First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases
With 300,000 square feet (27,870 square meters), it is the largest dedicated cell-and-gene-therapy manufacturing facility in the world
Facility to reach 200 full-time staff by end of 2018 and continue to recruit high-value positions as market demand increases
Washington DC (Newswire) — BioInformant has launched the “Market for Stem Cell Exosomes – Products, Services, & Technologies,” a global strategic report targeting the growing demand for exosome therapeutics, diagnostics, and research tools.
Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes will play a crucial role in the cell therapy movement.
Based in Washington, DC, BioInformant is the first and only market research firm to specialize in the stem cell industry. With more than a decade of experience in tracking the stem cell industry (2006 to present), BioInformant has a robust database on which to base future market predictions. Written for companies developing exosome-related products and technologies, the report analyzes strategic opportunities for commercializing products involving exosomes derived from stem cells, as well as other cell sources. [Read more…]
The possibilities arising from stem cells have resulted in great commercial interest, with potential applications ranging from their use in the reversal of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology assessment, and more. To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.
One of several large companies selling stem cell research products is Lonza Group. Others competitors include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and more.
In major news released today, Lonza Group from Basel, Switzerland, reported a record 1st quarter of 2016, recording its “strongest first quarter in history in terms of sales and earnings.”
Lonza has several different business divisions, including Pharma&Biotech, Specialty Ingredients, Custom Manufacturing, and more. One of these divisions is Lonza Bioscience (LBS), which develops and manufactures tools for life sciences researchers. In this April 26, 2016, press release, Lonza states: “Our healthy Bioscience Solutions business showed further improvement compared with the previous year, driven by product introductions and sound demand in all sub-segments.”
To learn more about Lonza’s role within the research products market, view “Stem Cell Research Products – Opportunities, Tools, and Technologies.
To learn more about Lonza’s record first quarter results, read the full press release issued by Lonza Group (below). [Read more…]
BioInformant, a specialized market research firm serving the life science industry, announces the release of its latest report, “Stem Cell Research Products: Opportunities, Tools & Technologies.” The report combines technology-derived market data with end-user survey findings, exploring current market conditions and providing guidance to companies looking to develop strategically positioned stem cell product lines.
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Several broad categories of stem cells exist, including: embryonic, perinatal, adult, and cancer stem cells. Of interest to researchers is the potential for the use of stem cells in regenerative medicine to treat conditions ranging from diabetes, to cardiovascular disease and neurological disorders. Also, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to pharmaceutical companies.
To facilitate this research, a vast stem cell research products market is emerging. Large companies selling stem cell research products include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Lonza, Clontech (a Takara Bio Company), and GE Healthcare Life Sciences. Products offered by these companies include: antibodies to stem cell antigens, bead-based stem cell separation systems, stem cell protein purification and analysis tools, tools for DNA and RNA-based characterization of stem cells, stem cell culture and media reagents, stem cell specific growth factors and cytokines, tools for stem cell gene regulation, a range of stem cell services, tools for in vivo and in vitro stem cell tracking, and stem cell lines.
“A more in-depth understanding of the needs of scientists studying stem cells is of growing importance as the field becomes more complex and funding sources become harder to obtain,” explained Cade Hildreth, President/CEO of BioInformant.com.
This market report includes:
- An overview of stem cell research applications, including priorities by segment
- A breakdown of stem cell product categories
- Market assessment, including grant, patent, clinical trial, and scientific publication rate analysis
- Overview of stem cell funding sources, trends, and amounts (domestic and international)
- Market size valuations
- Historical and future growth projections for the stem cell research products market
- Competitive analysis of stem cell research product companies
- Communications strategies for accessing the marketplace
- End-user survey of stem cell scientists
Released February 2016, “Stem Cell Research Products: Opportunities, Tools & Technologies ” explores current market conditions within the stem cell research products market, provides strategic guidance for competing within the industry, and quantifies important trends, metrics, and findings to guide the decision-making of competitors across the stem cell research products marketplace.
Click here to view the full Executive Summary and Table of contents for the report: https://bioinformant.wpengine.com/product/stem-cell-research-products-opportunities-tools-and-technologies/.
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.